| PUBLICATION DETAILS |
Publication Date
June 2004
|
I.S.B.N. (print)
0-476-00358-8 |
I.S.B.N. (electronic)
0-476-00461-6 |
|
|
|
| DEVELOPED BY |
New Zealand Guidelines Group (NZGG)
Level 10, Cigna House
40 Mercer Street
PO Box 10 665
Wellington
NEW ZEALAND
Phone: +64 4 471 4180
Fax: +64 4 471 4185
E-mail: info@nzgg.org.nz |
|
|
|
| ENDORSED BY |
|
| REQUIRED TOOLS |
Documents are in PDF format. You'll need the FREE Adobe Acrobat Reader to browse and print them.
|
|
|
 |
 |
| Management of Dyspepsia and Heartburn |
On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information.
Alternative analgesics/anti-inflammatories should be considered first. Co-therapy may be required to prevent adverse effects (eg, dyspepsia, gastrointestinal bleeding) in selected at-risk patients, The COX-2 drugs listed above should only be used after careful consideration of the risks, benefits and costs related to each specific patient where this choice is made. |
|
 |
PDF Format (2017.8 k)
Minimum Download Times (in seconds) - 56k: 288.3s 128k: 144.1s 256k: 72.1s |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We encourage readers to use this area to submit comments about the guidelines and to draw our attention to errors that inevitably will have been made in a project of this scope. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
